Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Ribozyme package effective against hepatitis B virus

23.03.2004


Penn State College of Medicine researchers have developed a tiny package that searches for and destroys up to 80 percent of hepatitis B virus in the livers of mice.



"This marks one of the few successful in vivo, or in-animal, models of an effective therapy to reduce the production of hepatitis B virus," said Gary Clawson, M.D., Ph.D., professor of pathology, biochemistry and molecular biology, Penn State College of Medicine. "Although this work focused on hepatitis B virus, our method of targeting and packaging ribozymes should also be applicable to the development of therapies to fight other viruses."

The study was published March 5 in the online version of the journal, Molecular Therapy, the official journal of the American Society of Gene Therapy, and will appear in the journal’s April print edition.


Hepatitis B virus (HBV) attacks the liver and can cause lifelong infection, liver cancer and, eventually, death. Although HBV is treated with drugs, it cannot be cured. The chronic disease affects about 1.25 million Americans, 20 percent to 30 percent of whom acquired the virus in childhood. HBV is transmitted via blood or sexual activity, but also may be transmitted from mother to child during childbirth. Once infected, the virus continues to reproduce in the liver.

Clawson, who is also director of the Jake Gittlen Cancer Research Center at Penn State Milton S. Hershey Medical Center, and his team developed the SNIPAA cassette, which contains a double-dose of a special type of ribozyme called a trans-acting hammerhead ribozyme. Ribozymes are ribonucleic acid (RNA) segments that, like enzymes, cause chemical changes or splitting in other RNA segments. RNA, which is critical to the replication of DNA - life’s instruction book - also is critical to the replication of viruses. The SNIPAA cassette was packaged in liposomes, typical vehicles for delivering drugs in the body, and the liposomes in turn were modified with proteins so that they would seek out the liver cells where the HBVs replicate.

Once at the liver cell, the SNIPAA cassette package is released into the cell and finds its way to the cell nucleus, where the active ribozymes are produced. The ribozymes destroy the viral RNA’s ability to produce proteins by cleaving, or cutting, the viral RNAs, rendering them useless. Proteins are critical to virus replication.

First, Clawson and co-workers used proprietary in vitro selection techniques to identify the best target sites in HBV RNA, and then used cells in culture to test the effectiveness of the cassette. In the cell cultures, he found that the SNIPAA cassette containing a double-dose of ribozymes eliminated more of the virus over a period of three to five days than did cassettes containing a single dose of the ribozymes.

Specialized transgenic mice, which contain the HBV in their DNA and which are chronic carriers of HBV, were treated with the tiny HBV-fighting packages. Clawson and co-workers chose the dosage and schedule of the drug delivery to the mice based on their cell culture work. Studies with the transgenic mice were performed with John Morrey, Ph.D., at Utah State, under the auspices of an NIH contract which supports testing of antiviral reagents.

"The treatment effects were quite dramatic," Clawson said. "We recorded a greater than 80 percent reduction in the HBV liver DNA, meaning far less virus was being produced, and staining for the virus using antibodies also showed a dramatic decrease in residual viral production. This is significant because there are so few examples of successful in vivo applications of ribozymes against bona fide naturally-occurring, disease-causing organisms."

Clawson believes this cassette is more effective than previous ones for a number of reasons. First, the best target sites were chosen using a "library selection" process. Second, the ribozyme cassette is engineered to cut itself into pieces, thereby freeing the HBV-targeted ribozymes from extraneous sequences that could interfere with their activity. In addition, Clawson’s cassette included two distinct trans-acting ribozymes, whereas previous versions included only one. With two trans-acting hammerhead ribozymes in the SNIPAA cassette, twice the amount of "medicine" was present and was delivered over a longer period.


Co-authors on the study were: Wei-Hua Pan, Pin Xin, Departments of Pathology and Biochemistry and Molecular Biology, The Gittlen Cancer Research Institute, Penn State Milton S. Hershey Medical Center, and John D. Morrey, Institute for Antiviral Research, Utah State University.

This work was supported by a research and development contract with Biosan Laboratories/Hexal AG and by a contract from the National Institutes of Health.

Valerie Gliem | EurekAlert!
Further information:
http://www.psu.edu/

More articles from Health and Medicine:

nachricht New study points the way to therapy for rare cancer that targets the young
22.11.2017 | Rockefeller University

nachricht Penn study identifies new malaria parasites in wild bonobos
21.11.2017 | University of Pennsylvania School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New proton record: Researchers measure magnetic moment with greatest possible precision

High-precision measurement of the g-factor eleven times more precise than before / Results indicate a strong similarity between protons and antiprotons

The magnetic moment of an individual proton is inconceivably small, but can still be quantified. The basis for undertaking this measurement was laid over ten...

Im Focus: Frictional Heat Powers Hydrothermal Activity on Enceladus

Computer simulation shows how the icy moon heats water in a porous rock core

Heat from the friction of rocks caused by tidal forces could be the “engine” for the hydrothermal activity on Saturn's moon Enceladus. This presupposes that...

Im Focus: Nanoparticles help with malaria diagnosis – new rapid test in development

The WHO reports an estimated 429,000 malaria deaths each year. The disease mostly affects tropical and subtropical regions and in particular the African continent. The Fraunhofer Institute for Silicate Research ISC teamed up with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME and the Institute of Tropical Medicine at the University of Tübingen for a new test method to detect malaria parasites in blood. The idea of the research project “NanoFRET” is to develop a highly sensitive and reliable rapid diagnostic test so that patient treatment can begin as early as possible.

Malaria is caused by parasites transmitted by mosquito bite. The most dangerous form of malaria is malaria tropica. Left untreated, it is fatal in most cases....

Im Focus: A “cosmic snake” reveals the structure of remote galaxies

The formation of stars in distant galaxies is still largely unexplored. For the first time, astron-omers at the University of Geneva have now been able to closely observe a star system six billion light-years away. In doing so, they are confirming earlier simulations made by the University of Zurich. One special effect is made possible by the multiple reflections of images that run through the cosmos like a snake.

Today, astronomers have a pretty accurate idea of how stars were formed in the recent cosmic past. But do these laws also apply to older galaxies? For around a...

Im Focus: Visual intelligence is not the same as IQ

Just because someone is smart and well-motivated doesn't mean he or she can learn the visual skills needed to excel at tasks like matching fingerprints, interpreting medical X-rays, keeping track of aircraft on radar displays or forensic face matching.

That is the implication of a new study which shows for the first time that there is a broad range of differences in people's visual ability and that these...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Ecology Across Borders: International conference brings together 1,500 ecologists

15.11.2017 | Event News

Road into laboratory: Users discuss biaxial fatigue-testing for car and truck wheel

15.11.2017 | Event News

#Berlin5GWeek: The right network for Industry 4.0

30.10.2017 | Event News

 
Latest News

Lightning, with a chance of antimatter

24.11.2017 | Earth Sciences

A huge hydrogen generator at the Earth's core-mantle boundary

24.11.2017 | Earth Sciences

Scientists find why CP El Niño is harder to predict than EP El Niño

24.11.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>